
Last update at 2026-06-23T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
BioSig Stock Surges Following Share Exchange Deal With Streamex
Mon 26 May 25, 04:42 PMReasons to Retain TransMedics Stock in Your Portfolio for Now
Fri 23 May 25, 02:36 PMAMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
Thu 22 May 25, 03:39 PMBAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
Wed 21 May 25, 02:48 PMSYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
Tue 20 May 25, 01:22 PMIs IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
Wed 14 May 25, 01:40 PMIs Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
Mon 28 Apr 25, 01:40 PMLFWD Stock Falls Despite Launch of Next-Generation Mobility ReWalk 7
Wed 16 Apr 25, 11:13 AMReasons to Add Fresenius Medical Stock to Your Portfolio Now
Fri 04 Apr 25, 04:37 PM| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Income before tax | -34.03200M | -191.63800M | -54.43700M | -29.94900M | -36.05200M |
| Minority interest | - | - | - | - | - |
| Net income | -33.99300M | -184.34900M | -52.44200M | -26.54700M | -31.54800M |
| Selling general administrative | 42.09M | 41.16M | 40.00M | 38.45M | 35.92M |
| Selling and marketing expenses | 103.14M | 102.82M | 104.25M | 95.30M | 81.31M |
| Gross profit | 157.71M | 154.70M | 174.25M | 165.73M | 156.79M |
| Reconciled depreciation | 25.80M | 27.71M | 30.87M | 29.35M | 25.92M |
| Ebit | -24.06200M | -33.84400M | -19.23300M | -19.00700M | -14.87000M |
| Ebitda | 1.74M | -6.13200M | 11.64M | 10.34M | 11.05M |
| Depreciation and amortization | 25.80M | 27.71M | 30.87M | 29.35M | 25.92M |
| Non operating income net other | - | - | -0.55400M | -0.79000M | 0.09M |
| Operating income | -39.95400M | -192.43500M | -19.23300M | -19.00700M | -14.87000M |
| Other operating expenses | 332.45M | 496.35M | 357.43M | 334.44M | 305.97M |
| Interest expense | - | 1.61M | 2.70M | 0.69M | 0.86M |
| Tax provision | -0.03900M | -7.28900M | -1.99500M | -3.40200M | -4.50400M |
| Interest income | - | - | - | - | - |
| Net interest income | 0.98M | 1.61M | -2.70200M | -0.68800M | -0.86100M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | 32.50M | 10.25M | 20.32M |
| Other items | - | - | - | - | - |
| Income tax expense | -0.03900M | -7.28900M | -1.99500M | -3.40200M | -4.50400M |
| Total revenue | 292.50M | 303.91M | 338.75M | 316.22M | 291.01M |
| Total operating expenses | 197.66M | 347.13M | 192.93M | 183.95M | 171.75M |
| Cost of revenue | 134.79M | 149.22M | 164.51M | 150.49M | 134.22M |
| Total other income expense net | 5.92M | 0.80M | -35.20400M | -10.94200M | -21.18200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -33.99300M | -184.34900M | -52.44200M | -26.54700M | -31.54800M |
| Net income applicable to common shares | - | - | -52.44200M | -26.54700M | -31.54800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Total assets | 280.14M | 317.67M | 532.64M | 552.75M | 561.44M |
| Intangible assets | 69.12M | 77.38M | 111.14M | 152.38M | 168.98M |
| Earning assets | - | - | - | - | - |
| Other current assets | 7.29M | 12.97M | 4.62M | 2.20M | 1.76M |
| Total liab | 97.17M | 112.08M | 154.34M | 128.26M | 121.98M |
| Total stockholder equity | 182.97M | 205.59M | 378.30M | 424.49M | 439.46M |
| Deferred long term liab | - | - | 12.81M | 16.04M | 19.95M |
| Other current liab | 42.91M | 50.91M | 43.38M | 21.46M | 37.95M |
| Common stock | 0.39M | 0.39M | 0.38M | 0.38M | 0.38M |
| Capital stock | 0.39M | 0.39M | 0.38M | 0.38M | 0.38M |
| Retained earnings | -429.19700M | -395.20400M | -210.85500M | -158.41300M | -131.86600M |
| Other liab | - | - | 17.38M | 24.20M | 37.08M |
| Good will | - | 0.00000M | 159.24M | 201.06M | 201.32M |
| Other assets | - | - | 49.22M | 10.96M | 3.81M |
| Cash | 55.89M | 76.06M | 44.62M | 28.82M | 48.16M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 76.20M | 91.16M | 83.83M | 74.32M | 57.58M |
| Current deferred revenue | - | - | -14.76100M | 16.04M | - |
| Net debt | -55.89300M | -71.32800M | 5.20M | 4.96M | -28.16100M |
| Short term debt | 1.84M | 1.98M | 14.76M | 8.78M | - |
| Short long term debt | - | 4.73M | 14.76M | 8.78M | - |
| Short long term debt total | 3.95M | 5.91M | 49.82M | 33.78M | 20.00M |
| Other stockholder equity | 613.80M | 604.77M | 593.49M | 581.16M | 567.79M |
| Property plant equipment | - | - | 44.38M | 45.01M | 37.07M |
| Total current assets | 168.32M | 193.25M | 163.54M | 143.34M | 140.88M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | 378.30M | 71.05M | 69.16M |
| Short term investments | - | - | - | - | - |
| Net receivables | 43.14M | 43.61M | 52.83M | 52.30M | 35.41M |
| Long term debt | - | - | 49.82M | 25.00M | 20.00M |
| Inventory | 62.01M | 60.62M | 55.33M | 51.39M | 48.61M |
| Accounts payable | 33.29M | 37.75M | 40.45M | 28.05M | 19.63M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -2.02300M | -4.36500M | -4.72300M | 1.36M | 3.15M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.38M | 0.38M | 0.38M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -210.85500M | -158.41300M | -131.86600M |
| Treasury stock | - | - | -5.71400M | -5.71400M | -5.71400M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 10.40M | 5.57M | 54.33M | -5.07400M | 13.19M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 111.82M | 124.42M | 369.10M | 409.41M | 420.56M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | 49.82M | 25.00M | 20.00M |
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Investments | -10.17800M | 123.72M | -9.74600M | -11.41000M | -8.52400M |
| Change to liabilities | - | - | 2.14M | 3.91M | 4.88M |
| Total cashflows from investing activities | -10.17800M | - | -9.74600M | -19.30700M | -13.71100M |
| Net borrowings | 0.00000M | - | 24.25M | 5.00M | -20.00000M |
| Total cash from financing activities | -0.25500M | -64.24800M | 25.42M | 7.68M | -16.98600M |
| Change to operating activities | - | - | 0.33M | -5.01200M | -3.18100M |
| Net income | -33.99300M | -184.34900M | -52.44200M | -26.54700M | -31.54800M |
| Change in cash | -20.16300M | 31.44M | 15.79M | -19.33600M | -6.27400M |
| Begin period cash flow | 76.06M | 44.62M | 28.82M | 48.16M | 54.44M |
| End period cash flow | 55.89M | 76.06M | 44.62M | 28.82M | 48.16M |
| Total cash from operating activities | -10.12800M | -28.15800M | 0.08M | -7.19400M | 24.09M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 25.80M | 27.71M | 30.87M | 29.35M | 25.92M |
| Other cashflows from investing activities | -5.71400M | - | -5.93400M | -15.01000M | -8.52400M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -1.34700M | -9.41000M | -8.19800M | -2.79600M | 11.54M |
| Change to account receivables | 0.02M | 7.89M | -1.29900M | -17.15100M | -4.16200M |
| Sale purchase of stock | -1.67000M | - | - | - | - |
| Other cashflows from financing activities | -4.74700M | -15.00000M | 0.42M | 2.68M | -13.71100M |
| Change to netincome | - | - | 28.50M | 11.05M | 23.00M |
| Capital expenditures | 4.46M | 5.77M | 4.35M | 4.30M | 13.71M |
| Change receivables | - | - | -1.29900M | -17.15100M | -4.16200M |
| Cash flows other operating | - | - | 0.51M | -6.28100M | -5.53000M |
| Exchange rate changes | - | - | - | - | 0.33M |
| Cash and cash equivalents changes | - | - | 15.75M | -18.81800M | -6.27400M |
| Change in working capital | -14.11200M | 14.42M | -7.02600M | -21.04700M | 9.07M |
| Stock based compensation | 9.77M | 10.53M | 11.16M | 10.69M | 8.62M |
| Other non cash items | 3.39M | 111.50M | 19.82M | 4.07M | 16.83M |
| Free cash flow | -14.59200M | -33.92600M | -4.27400M | -11.49100M | 10.38M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ANGO AngioDynamics Inc |
-0.02 0.16% | 12.37 | - | 96.15 | 1.41 | 2.56 | 1.29 | 147.24 |
| ISRG Intuitive Surgical Inc |
0.23 0.06% | 403.18 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOF EssilorLuxottica Société anonyme |
- -% | 192.00 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-0.49 0.51% | 95.87 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
3.21 2.28% | 143.92 | 25.56 | 12.48 | 2.59 | 1.76 | 2.89 | 12.55 |
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
14 Plaza Drive, Latham, NY, United States, 12110
| Name | Title | Year Born |
|---|---|---|
| Mr. James C. Clemmer | CEO, Pres & Director | 1964 |
| Mr. Stephen A. Trowbridge | Exec. VP & CFO | 1974 |
| Mr. David D. Helsel | Sr. VP of Global Operations and R&D | 1964 |
| Mr. Chad T. Campbell | Sr. VP & GM of Vascular Access Global Bus. Unit | 1971 |
| Ms. Laura Piccinini | Sr. VP & GM of International | 1970 |
| Mr. Richard C. Rosenzweig | Sr. VP, Gen. Counsel & Company Sec. | 1967 |
| Mr. Benjamin H. Davis | Sr. VP of Bus. Devel. | 1964 |
| Ms. Marna I. Bronfen-Moore | Sr. VP of HR | 1967 |
| Mr. Warren G. Nighan | Sr. VP of Quality & Regulatory Affairs | 1969 |
| Ms. Kim L. Seabury | Sr. VP of Information Technology | 1967 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.